CLYM · Climb Bio, Inc.

Climb Bio, Inc. (Nasdaq: CLYM) announced a $110.0 million private placement of common stock and pre-funded warrants, led by Leerink Partners and Piper Sandler. The transaction involves the sale of 9,481,000 shares at $9.50 per share and 2,106,000 pre-funded warrants at $9.4999 per warrant, with an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and subject to beneficial ownership limitations (4.99% or 9.99% per holder, 33.0% for RA Capital). The company expects to close the offering on April 29, 2026, and will file a resale registration statement within 45 days thereafter. Proceeds are intended to support late-stage development of budoprutug and CLYM116. The offering was conducted under Section 4(a)(2) of the Securities Act and Regulation D, with no general solicitation. This capital raise significantly strengthens Climb Bio's balance sheet, providing runway for key clinical milestones.